These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development of Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007 [TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with Al-Saden N; Lam K; Chan C; Reilly RM Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952 [TBL] [Abstract][Full Text] [Related]
5. Development and preclinical studies of Lam K; Chan C; Reilly RM MAbs; 2017 Jan; 9(1):154-164. PubMed ID: 27813707 [TBL] [Abstract][Full Text] [Related]
6. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962 [TBL] [Abstract][Full Text] [Related]
7. Noninvasive Detection of HER2 Expression in Gastric Cancer by Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [ Chan C; Fonge H; Lam K; Reilly RM Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737 [TBL] [Abstract][Full Text] [Related]
9. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with McKnight BN; Viola-Villegas NT Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299 [TBL] [Abstract][Full Text] [Related]
11. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070 [TBL] [Abstract][Full Text] [Related]
12. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability. Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317 [TBL] [Abstract][Full Text] [Related]
13. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889 [TBL] [Abstract][Full Text] [Related]
14. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Razumienko E; Dryden L; Scollard D; Reilly RM Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982 [TBL] [Abstract][Full Text] [Related]
15. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305 [TBL] [Abstract][Full Text] [Related]
16. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET. Moreau M; Poty S; Vrigneaud JM; Walker P; Guillemin M; Raguin O; Oudot A; Bernhard C; Goze C; Boschetti F; Collin B; Brunotte F; Denat F Dalton Trans; 2017 Oct; 46(42):14659-14668. PubMed ID: 28861553 [TBL] [Abstract][Full Text] [Related]
17. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. McLarty K; Cornelissen B; Cai Z; Scollard DA; Costantini DL; Done SJ; Reilly RM J Nucl Med; 2009 Aug; 50(8):1340-8. PubMed ID: 19617342 [TBL] [Abstract][Full Text] [Related]
18. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425 [TBL] [Abstract][Full Text] [Related]
19. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604 [TBL] [Abstract][Full Text] [Related]
20. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]